Clinical Trial Update: Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis [Phase 2]

View source ↗

Summary

Phase 2 trial of LAS41007 for actinic keratosis has completed, reporting efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LAS41007

Snippet

Sponsor: Almirall, S.A. | Conditions: Actinic Keratosis | Phase 2 | Status: COMPLETED